Poznan

• Dual Antithrombotic Therapy with Dabigatran and Ticagrelor in Patients with Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Und … Ended
  2024-515056-20-00 5 2021-07-31 Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoin
• Study of efficacy, safety, and tolerability of LNA043 in patients with symptomatic knee osteoarthritis Ended
  2023-509937-37-00 4 2021-07-21 Osteoarthritis
• A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenan … Ended
  2024-513569-38-00 10 2021-07-09 Crohn's Disease
• Eptinezumab as Preventive Treatment of Migraine in Adults with Migraine Ended
  2023-510183-12-00 5 2021-07-05 Chronic migraine
• Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain M … Ended
  2023-506315-17-00 9 2021-06-25 Advanced melanoma with brain metastases, PD-1 refractory or PD-1 naiv
• The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy Ended
  2023-510174-13-00 5 2021-06-17 Chronic Obstructive Pulmonary Disease (COPD)
• The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD) Ended
  2023-510175-60-00 5 2021-06-16 Chronic obstructive pulmonary disease (COPD) and Chronic Bronchitis
• A Study of Subcutaneous Nivolumab in Previously Treated Advanced or Metastatic Clear Cell Renal Cell Carcinoma Ended
  2023-503280-42-00 5 2021-06-01 Metastatic Clear Cell Renal Cell Carcinoma
• Phase 2 study of Pembrolizumab given every 6 weeks to participants diagnosed with Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL … Ended
  2024-510979-38-00 4 2021-05-27 Relapsed or refractory Classical Hodgkins Lymphoma and relapsed or ref
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) Ended
  2023-506918-45-00 5 2021-05-17 Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Ended
  2023-506919-18-00 5 2021-05-17 Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
• A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab … Ended
  2023-507317-10-00 5 2021-05-10 Locally advanced, unresectable, or metastatic non small cell lung canc
• "A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with … Ended
  2023-505787-11-00 5 2021-04-29 Severe and inadequately controlled asthma
• Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's … Ended
  2023-504990-19-00 5 2021-04-06 Agitation in Patients With Dementia of the Alzheimer's Type
• Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Ga … Ended
  2023-504834-23-00 11 2021-02-24 Advanced/Metastatic Gastroesophageal Adenocarcinoma
• Pembrolizumab + Lenvatinib for First Line Non-Clear Cell, Renal Cell Carcinoma Ended
  2023-504944-32-00 4 2021-02-17 Non-clear Cell Renal Cell Carcinoma
• Study to Investigate the Efficacy and Safety of CS1003 in Combination with Lenvatinib Compared to Placebo in Combination with Lenvatinib in … Ended
  2024-517331-48-00 5 2021-01-18 Unresectable advanced hepatocellular carcinoma
• A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experien … Ended
  2023-507415-35-00 5 2021-01-15 Psoriatic Arthritis
• Phase I/II, First in Human, Dose Escalation Trial of TL-895 Monotherapy in Subjects with Relapsed/Refractory B-Cell Malignancies and Expansi … Ended
  2024-516691-14-00 7 2021-01-05 B Cell Malignancies and Chronic Lymphocytic Leukemia or Small Lymphocy
• TSRO-Ph2, Dostarlimab +CT vs Pembro +CT, 1L H2H efficacy comparison in Metastatic NSCLC pts. PERLA Ended
  2023-505894-33-00 4 2020-11-25 Lung Cancer, Non-Small Cell
• Substudy to test investigational agents with pembrolizumab in combination with chemotherapy in treatment-naïve NSCLC in a rolling arm design Ended
  2023-506932-33-00 4 2020-10-20 non-small cell lung cancer
• Substudy to test investigational agents in combination with pembrolizumab in PD-L1 positive treatment-naïve NSCLC in a rolling arm design Ended
  2023-506933-32-00 4 2020-10-20 Non-small Cell Lung Cancer (NSCLC)
• Substudy to test investigational agents in combination with pembrolizumab in patients with PD-(L)1 refractory NSCLC in a rolling-arm design Ended
  2023-506934-56-00 4 2020-10-20 Non-small Cell Lung Cancer
• A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents Ended
  2024-512837-34-00 5 2020-10-14 Episodic and Chronic Migraine

Showing 841–864 of 914 trials